Fig. 1From: Empagliflozin prevents doxorubicin-induced myocardial dysfunctionLV systolic function. Mice treated with DOX presented a significant reduction of LV function parameters compared to baseline. On the other hand, mice in the DOX + EMPA group had a significantly better LV function compared to the DOX groupBack to article page